NSC2805 | 4371-34-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: NSC2805
• 英文别名: 4,4'-Dimethyl[1,1'-biphenyl]-2,2',5,5'-tetrol；2-(2,5-dihydroxy-4-methylphenyl)-5-methylbenzene-1,4-diol
• CAS: 4371-34-0
• 化学式: C₁₄H₁₄O₄
• 分子量: 246.263
• InChiKey: DSVRCBOSZSZMRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  NSC2805 生成 4,4'-二甲基-1,1'-联苯-2,2',5,5'-四酮
  参考文献：
  名称：

  ALBEROLA, A.;GONZALEZ, A. M.;PULIDO, F. J., REV. ROUM. CHIM., 1984, 29, N 5, 441-446

  摘要：

  DOI：
• 作为产物：
  描述：

  邻甲酚 在 双氧水 、 iron(II) sulfate 作用下， 生成 NSC2805
  参考文献：
  名称：

  ON THE REACTION BETWEEN CRESOLS AND HYDROGEN PEROXIDE IN THE PRESENCE OF FERROUS SULPHATE

  摘要：

  DOI：

  10.1246/bcsj.11.132

文献信息

• Fusion genes associated with progressive prostate cancer
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US10167519B2

  公开（公告）日：2019-01-01

  The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

  本发明涉及用于确定患有前列腺癌的受试者是否有更大风险发展为进展性疾病的方法和组合物，以及治疗受试者的方法。本发明至少部分基于以下发现：约 90% 的男性携带至少一种以下融合基因：TRMT11-GRIK2、SLC45A2-AMACR、MTOR-TP53BP1、LRRC59-FLJ60017、TMEM135-CDC67 和 CCNH-05orf30 的男性在前列腺癌根治术后出现前列腺癌复发、转移和/或前列腺癌特异性死亡（均为 "进展性前列腺癌 "的例子），而未携带任何这些融合基因的男性中仅有 36% 出现这些结果。至少部分原因还在于，研究发现，如果原发性前列腺癌含有 TRMT11-GRIK2 或 MTOR-TP53BP1 融合基因，则没有患者能存活五年而不复发。该研究还至少部分基于发现 MAN2A1-FER 融合基因编码的蛋白质具有激酶活性。
• Inhibitors of SARM1 NADase activity and uses thereof
  申请人：Washington University

  公开号：US11253503B2

  公开（公告）日：2022-02-22

  The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

  本公开提供了可用作 SARM1 NAD 酶活性抑制剂的化合物、其组合物及其使用方法。本公开提供了用于治疗神经退行性或神经疾病或紊乱的化合物、其组合物以及使用方法。
• Methods of treating cancers containing fusion genes
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US11384400B2

  公开（公告）日：2022-07-12

  The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

  本发明涉及治疗携带一种或多种特定融合基因的癌症患者的方法。本发明至少部分基于以下发现：MAN2A1-FER 融合基因编码的蛋白质具有激酶活性，在前列腺癌以外的癌症（如肝细胞癌）中使用靶向 MAN2A1-FER 的酪氨酸激酶抑制剂可显著提高异种移植癌症动物的存活率。
• Erdtman, Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences, 1934, vol. 143, p. 196,197
  作者：Erdtman

  DOI：——

  日期：——
• FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：EP3090062A1

  公开（公告）日：2016-11-09